Crossmark

Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor

Crossref DOI link: https://doi.org/10.1007/s11605-020-04843-9

Published Print: 2021-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cavnar, Michael J. https://orcid.org/0000-0002-6197-7945
Seier, Kenneth

Gönen, Mithat

Curtin, Christina

Balachandran, Vinod P.

Tap, William D.

Antonescu, Cristina R.

Singer, Sam

DeMatteo, Ronald P.
Funding

Funding for this research was provided by:

National Institutes of Health (R01 CA102613)

The David Foundation

Betsy Levine-Brown and Marc Brown

GIST Cancer Research Fund

David and Monica Gorin

Kristin Ann Carr Fellowship
License Information

Text and Data Mining valid from 2021-07-01
More Information

This article is maintained by: Elsevier

Article Title: Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor

Journal Title: Journal of Gastrointestinal Surgery

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s11605-020-04843-9

Content Type: article

Copyright: Copyright © 2020 Society for Surgery of the Alimentary Tract. Published by ELSEVIER INC. All rights reserved. Published by Elsevier Inc. All rights reserved.